Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc to acquire Idenix Pharmaceuticals Inc


Monday, 9 Jun 2014 07:30am EDT 

Merck & Co Inc and Idenix Pharmaceuticals Inc:Says the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.The transaction, which values the purchase of Idenix at about $3.85 billion, has been approved by the boards of directors of both companies.Upon the completion of the tender offer, Merck will acquire all remaining shares through a second-step merger.The companies expect the transaction to close in the third quarter of 2014.Credit Suisse acted as financial advisor to Merck in this transaction and Hughes Hubbard & Reed LLP as its legal advisor.Centerview Partners acted as financial advisor to Idenix and Sullivan & Cromwell as its legal advisor. 

Company Quote

58.91
0.49 +0.84%
19 Aug 2014